Adalta Ltd. · ASX:1AD
Adalta — Investor Presentation (June 2018)
20 slides from Adalta's investor presentation, Jun 5, 2018
Slide 1: AdAlta Investor Presentation
AdAlta Investor Presentation June 2018 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au
Slide 2: Disclaimer
Disclaimer Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or invitation for subscript
Slide 3: AdAlta (1AD) investment summary
AdAlta (1AD) investment summary A drug discovery and development company using its powerful technology platform to generate a promising new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases. Investment highlights Initial focus on treating fibrosis – high u
Slide 4: Financial position
Financial position Key financial details Share performance (last 12 months) ASX code 1AD Share price (31st May 2018) AU$0.35 Market capitalisation AU$35.65m Shares on issue* 101,845,845 Escrowed shares (August 2018) 24,000,000 Options on issue 4,090,866 Current cash (31 March 2018) AU$3.63m Trading
Slide 5: Extensive support from institutional investors and HNWs
Extensive support from institutional investors and HNWs Top 20 shareholders 83% 64% institutional shareholders Australian based venture capital $40m fund 10% HNWs with >500K shares each 5% founding academic $27b under management, global institutions equities investor 3.46% Board and Management and 4
Slide 6: Management and Board in place to deliver strategy
Management and Board in place to deliver strategy Sam Cobb: Founding CEO and Director Dr John Chiplin: Independent Director Extensive experience in raising equity, contract and CEO of investment Company NewStar Ventures grant funding Managing Director of acquired antibody company 15 years of commerc
Slide 7: Scientific Advisory Board
Scientific Advisory Board Internationally recognised with proven track record of drug development Dr Mick Foley, AdAlta CSO John Westwick: pulmonary drug Expert in phage display discovery and development NIH, NHMRC, ARC, Gates funding and over 70 Over 14 years experience at Novartis, head of scienti
Slide 8: Market opportunity for IPF
Market opportunity for IPF Idiopathic Pulmonary Fibrosis (IPF) is an irreversible, unpredictable and incurable disease THE STATISTICS People living with IPF 300,000 People die from IPF every year 40,000 Median length of survival after IPF diagnosis 3.8 years 8
Slide 9: AD-214 for the treatment of IPF
AD-214 for the treatment of IPF Extensive pre-clinical data package with i-body demonstrates positive in vitro and in vivo in models of IPF Normal In the bleomycin mouse model of fibrosis the anti-CXCR4 i- lung tissue body has several effects in both therapeutic and prophylactic modes: – Inhibits fi
Slide 10: CXCR4 novel target for treatment of IPF
CXCR4 novel target for treatment of IPF Significant literature to support hypothesis CXCR4 of Normal human Diseased IPF the involvement of CXCR4 in fibrosis lung tissue lung tissue IPF diseased lung tissue has increased CXCR4 expression compared with normal lung tissues AD-214 has unique activity co
Slide 11: Global market interest in fibrosis treatments
Global market interest in fibrosis treatments Fibrosis assets acquired at an early stage – typically based on Phase I results Date Company Target Acquired by Deal value (US$) Deal commentary Sep-15 Adheron SDP051 Roche $105M upfront, plus SDP-51 at end of Phase I for IPF Therapeutics $475M in milest
Slide 12: IPF Phase II readouts generate $1.4 billion market value
IPF Phase II readouts generate $1.4 billion market value (NASDAQ:FGEN) $869 million added to its market cap on announcement (7 August 2017) of meeting primary endpoint in Phase IIb study Pamrevlumab (FG-3019) 103 patients 48 weeks (Euronext:GLPG; NASDAQ:GLPG) $555 million added to market cap on anno
Slide 13: AD-214 has broad application in treating fibrosis
AD-214 has broad application in treating fibrosis AdAlta data shows that its lead anti- CXCR4 i-body candidate can improve fibrosis across a range of fibrotic diseases LUNG: Idiopathic Pulmonary Fibrosis Lung Eye Liver EYE: Wet Age Related Macular Degeneration IPF Wet-AMD & PVR NASH & CIRRHOSIS LIVE
Slide 14: AD-214 development: key milestones
AD-214 development: key milestones 2018 2019 2020 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Manufacturing Toxicology Partnering of lead studies candidate based on other Phase I benchmark deals Publication of data Development of i-body pipeline BD and partnerships 14
Slide 15: AdAlta business model – strategy to create value
AdAlta business model – strategy to create value Pharma & biotech partnerships Revenues: Upfronts, i-body FTEs, milestones & royalties i-bodies new technology drug class platform and Potential in multiple library In-house disease indications Licence to pipeline of pharma drug Revenues: major Long lo
Slide 16: Market benchmarks
Market benchmarks Fibrosis Sep-15 acquired by Roche Aug-15 acquired by BMS Nov-14 acquired by BMS lead AD-214 $105m + $475m milestones $150m + $1.25b milestones $444m phase I asset phase IIa asset phase I asset Next gen April-16 with Abbvie Feb-18 with Seattle Genetics Feb-18 with Sanofi antibodies
Slide 17: Significant achievements 2017/18
Significant achievements 2017/18 ✓ Orphan Drug Designation (US FDA) of AdAlta i-body for treatment of IPF ✓ Completion of additional pre-clinical animal models in diseases of the lung, kidney, skin; strengthening broad anti-fibrotic data package of anti-CXCR4 i-body ✓ Publication of key data in Scie
Slide 18: Expected news flow
Expected news flow H1 2018 ✓ Publication of AD-114 data in Scientific Reports demonstrating i-body application of pulmonary fibrosis with human tissue and animal model data ✓ Investor and analyst briefing detailing application of the i-body for the undruggable targets such as GPCRs and ion channels
Slide 19: AdAlta summary
AdAlta summary Initial focus on treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases - high unmet clinical need AD-214 has significant pre-clinical validation demonstrating broad anti-fibrotic and anti- inflammatory effects as well as safety AD-214 orphan drug designation with FD
Slide 20: Contact us: Sam Cobb, CEO
Contact us: Sam Cobb, CEO s.cobb@adalta.com.au www.adalta.com.au 20